title: Clinical features associated with improvement of fatty liver disease.
abstract: BACKGROUND
  We presumed that identification of the factors associated with improvement of fatty livers disease (FLD) would support the therapeutic options for FLD. The goal of this study was to clarify what clinical characteristics are associated with biochemical and sonographic improvements in the non-alcoholic population with fatty livers.
  
  
  METHODS
  A total of 615 non-alcoholic men had elevated alanine aminotransferase (ALT) (> or = 40 IU/L) levels and sonographic evidence of a fatty liver, and their clinical characteristics were assessed at the beginning of the study and after 1 year of follow up. The improvement was defined as combination of normal ALT level and negative sonography for hepatic fat after 1 year. Programmed intervention or medications were not applied in this study population.
  
  
  RESULTS
  The overall rate of improvement of FLD after a 1-year follow up was 37/615 (6.0%). The improvement was strongly associated with decrement of changes in bodyweight, body mass index, waist circumference, gamma-glutamyltransferase, fasting blood sugar, total cholesterol, triglycerides, low-density lipoprotein cholesterol, total cholesterol/high-density lipoprotein cholesterol ratio and homeostasis model assessment. Multivariate analysis showed that decrement of changes in bodyweight (odds ratio (OR) = 1.56; 95% confidence interval (95%CI): 1.27-1.92) per 1 kg, body mass index (OR = 2.42; 95%CI: 1.58-3.71) per 1 SD (0.8 kg/m2), waist circumference (OR = 2.13; 95%CI: 1.02-4.54) per 1 cm, and low-density lipoprotein cholesterol (OR = 1.64; 95%CI: 1.05-2.56) per 1 SD (22 mg/dL) were all independent predictors for improvement of FLD.
  
  
  CONCLUSIONS
  These results suggest that the reduction of bodyweight is a major key point for the improvement of FLD.
authors.affiliation: Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.
authors.forename: S H
authors.initials: SH
authors.lastname: Park
authors.forename: B I
authors.initials: BI
authors.lastname: Kim
authors.forename: H J
authors.initials: HJ
authors.lastname: Kim
authors.forename: H
authors.initials: H
authors.lastname: Kim
authors.forename: S H
authors.initials: SH
authors.lastname: Kim
authors.forename: D I
authors.initials: DI
authors.lastname: Park
authors.forename: Y K
authors.initials: YK
authors.lastname: Cho
authors.forename: I K
authors.initials: IK
authors.lastname: Sung
authors.forename: C I
authors.initials: CI
authors.lastname: Sohn
authors.forename: W K
authors.initials: WK
authors.lastname: Jeon
authors.forename: D K
authors.initials: DK
authors.lastname: Keum
mesh_terms: D000328:Adult; D000368:Aged; D000410:Alanine Transaminase / Q000097:blood*; D000704:Analysis of Variance; D001823:Body Composition; D015992:Body Mass Index; D008078:Cholesterol, LDL / Q000097:blood*; D015331:Cohort Studies; D016001:Confidence Intervals; D005234:Fatty Liver / Q000175:diagnosis* / Q000453:epidemiology; D005500:Follow-Up Studies; D006801:Humans; D007723:Korea / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011237:Predictive Value of Tests; D011336:Probability; D012075:Remission, Spontaneous; D012307:Risk Factors; D018608:Ultrasonography, Doppler
chemical_list: D008078:Cholesterol, LDL; D000410:Alanine Transaminase